You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 21, 2013

Plant Variety Protection: New Announcement Impacts IP Rights and Profit Sharing

Informed Counsel

In Thailand, the Plant Varieties Protection Act B.E. 2542 (1999) provides protection for plant varieties that possess novelty, stability, uniformity, and distinctiveness. Once protected, the rights holder of a new plant variety has the sole right to produce, sell, distribute, import, export, or possess the plant for any of these purposes.

Section 52 of the Plant Varieties Protection Act stipulates that a person who collects, procures, and gathers wild plant varieties and general domestic plant varieties for the purpose of developing new varieties, education, research, and studies for commercial interests may do so with a valid permit granted by the Department of Agriculture (DOA). The permit holder (known as the “grantee”) must also enter into a profit-sharing agreement with the DOA (the grantor), which requires that any monetary gains from the commercial exploitation of such plant variety(ies) be shared with the DOA.

Although the Plant Varieties Protection Act took effect in 1999, the DOA only issued an “Announcement Regarding Forms for Application for Permission and Profit-Sharing Agreement under Section 52” (the Announcement) on January 29, 2013. This article will provide an overview of the key provisions of the Announcement as they relate to intellectual property rights and the profit-sharing scheme.

Intellectual Property Rights

The Announcement clearly sets out that the grantee does not have any intellectual property right or other rights to the plant varieties and/or parts thereof covered by the permit. The grantee is, however, allowed to use the plant varieties that are collected, procured, or gathered or the results from the developments, studies, and research for commercial purposes.

If these activities result in new creations, the grantee is entitled to seek intellectual property protection for the resulting products or innovations. In doing so, the grantee must inform the DOA of any intellectual property rights filings. If the grantee decides not to apply for IP protection, it must notify the DOA, and the DOA will have a right of first refusal as to whether it wishes to apply for the IP protection on the creations/innovations, and to negotiate with the grantee as to whether the rights in the creations/innovations will be assigned to the DOA, with or without consideration. If the DOA declines to acquire such right or the negotiation fails, the grantee can then assign its right to a third party. Any considerations received from the assignment are considered as use for commercial purpose, and hence the grantee is obligated to share the profits with the DOA.

Profit Sharing

If the grantee uses the plant varieties and/or parts thereof that are collected, procured, or gathered or that result from the developments, studies, and research for commercial purposes, the grantee must share the profits from these activities with the DOA. The profits can be shared in the form of property, technological advances, technology transfer, personnel development, or any other types of profits. This will be determined according to the approved profit-sharing proposal based on net sales or proceeds from the services resulting from such commercial use.

If the grantee allows or authorizes a third party to manufacture, use, or yield any profits from the products developed employing the protected IP rights acquired through use or development of the plant varieties, the grantee needs to inform the DOA and share the profits from this arrangement. The duty to share the benefit continues for as long as the grantee obtains the commercial benefits, but no longer that the period of IP protection.

If the grantee acts as an agent for another person, the profits will be calculated from the profits obtained by the principal. However, the grantee is obligated to share these profits with the DOA as if the profits were obtained by the grantee.

Implications for Grantees

If you are a grantee, what does the Announcement mean for you? Neither the Plant Varieties Protection Act nor the Announcement provides a specific definition of “profit,” but it appears to include:

  • Consideration received in exchange for an assignment or authorization for other parties to use the IP.
  • Net sales of products developed employing the protected IP rights acquired through use or development of the plant varieties.

As a grantee, you are obligated to share any such profits with the DOA. Regardless of whether you commercially exploit the IP right yourself or assign it to others, you continue to have the duty to share the profit.

The Announcement holds that you can share profits as property, technological advances, technology transfer, personnel development, or any other types of profits, but it lacks guidelines on the rate and amount to be shared. It is uncertain whether you can negotiate the profit sharing or whether the DOA will impose a specific rate and amount.

Further, the Announcement stipulates that your duty to share the benefit continues for as long as you enjoy such commercial benefits, but no longer than the period of IP protection. While this appears to be a very straightforward statement, in reality it could be difficult to reduce into practice. For example, if you will share the profits in the form of technology transfer or personnel development, how can you quantify the appropriate amount of consideration for profit-sharing purposes?

This lack of clarity regarding how profits will be shared, combined with the requirement to approve a profit-sharing scheme at an early stage of the process, may discourage investment in research and studies on plant varieties. Innovators will therefore need to closely monitor for further guidelines or directions on how these procedures will be implemented in practice, so that they can be assured that their research investments will be worthwhile.

RELATED INSIGHTS​ 

July 9, 2026
Recycling, upcycling, and refill-packaging models are now widely promoted as ways to reduce waste, lower carbon emissions, and respond to consumer demand for sustainable products. However, complications arise when these environmentally driven trends intersect with intellectual property law—particularly where reused or altered packaging continues to display third parties’ registered trademarks. Adding to this complexity, Thailand’s draft Sustainable Packaging Management Act aims to introduce new environmental compliance obligations that businesses must navigate alongside existing trademark concerns. Recycling and upcycling packaging may infringe trademark rights, especially in cases not protected by the first-sale doctrine—the principle that a trademark owner’s rights over a particular mark-bearing product end once the owner first sells it. Furthermore, even refill packaging carries legal risk due to specific statutory prohibitions under Thai law. Compounding these challenges, the draft Sustainable Packaging Management Act will impose extended producer responsibility (EPR) obligations on manufacturers and brand owners, requiring them to manage packaging throughout its lifecycle. These overlapping legal frameworks could deter manufacturers from pursuing ESG-aligned business models unless businesses understand how to navigate both trademark and environmental requirements. Under Thai law, this issue remains uncertain because the Trademark Act does not expressly codify the first sale doctrine, also known as the exhaustion of trademark rights. Generally, this doctrine provides that once a trademark owner has lawfully sold goods bearing its trademark, the owner’s right to control further resale of those particular goods is exhausted. The rationale is that the owner has already received commercial benefit from the first authorized sale; therefore, the purchaser should be free to resell or otherwise dispose of the goods. Although the doctrine is not expressly codified in the Trademark Act, Thai courts have recognized it in relation to genuine goods and parallel imports, as seen in a Supreme Court Judgment No. 2817/2543 in which the
July 6, 2026
Indonesia’s regulation on reporting online intellectual property (IP) infringement provides comprehensive procedural guidance for IP rights holders and their licensees in reporting online infringement complaints. Issued in December 2025 by the Ministry of Law as Regulation No. 47 of 2025 regarding Handling of Intellectual Property Infringement Reports in Electronic Systems, this regulation covers all types of IP rights. It also specifies documentation when reporting infringement, and lays out the procedures for examination, verification, and enforcement actions. Submission of Complaints Complainants may submit reports through the online system of the Directorate General of Intellectual Property (DGIP) or in person at the DGIP office. Complaints may also be filed through an authorized proxy. Under the regulation, complainants are required to provide the following information and documents: Personal details of the complainant; Brief description of the protected work or subject matter (i.e., type of IP and name or address of the infringing website, portal, account, or application, or a link to the location of the infringing content); Complete description of the alleged infringement; Certificate of registration or recordal of the relevant IP; Recordal of IP license agreement, if any; and Other supporting evidence. Verification and Examination Process Upon receiving a complaint, the responsible formality officer may request clarification or additional supporting documents. In the latter case, the complainant must then submit the necessary administrative documents within 14 days of the notification date. Once the documentation is deemed complete and sufficient, the case will be formally registered. Subsequently, the DGIP will establish a verification team to handle online IP violations, which will include the Civil Servant Investigator (PPNS), the Ministry of Communication and Digital Affairs, experts with relevant expertise in IP, and representatives from related associations such as AVISI (Indonesian Video Streaming Association). After examining the report, the team will prepare the Minutes
June 30, 2026
Customs recordation is an enforcement mechanism in Myanmar that enables intellectual property (IP) rights holders to seek prevention of the cross-border movement of infringing goods. The enactment of Myanmar’s IP laws in 2019 has enabled customs recordation for registered marks and copyrights under the Trademark Law 2019 and the Copyright Law 2019. By contrast, the Patent Law 2019 and the Industrial Design Law 2019 do not provide a practical framework for customs recordation, and accordingly such rights are not subject to the customs recordation regime. Under the Trademark Law 2019, rights holders may apply for customs recordation and may also ask the Customs Department to suspend the release of goods suspected of bearing counterfeit marks. Likewise, the Copyright Law 2019 allows for customs intervention in relation to pirated works. These provisions reflect Myanmar’s gradual alignment with international standards on border measures, although the implementation framework remains at a relatively early stage of development. Customs Recordation Pursuant to the Trademark Law 2019 and the Copyright Law 2019, the relevant authorities have issued customs rules concerning the protection of registered marks and copyrights. In practice, the process generally begins with the submission of an application to the Customs Department together with supporting documentation. This typically includes proof of registration in Myanmar; details of the rights holder, applicant, and any authorized representative; and a comprehensive description of the genuine goods. Product identification materials—such as photographs, packaging samples, and distinguishing features—are particularly important in helping customs officers identify suspected infringing goods. A recordation remains valid for two years from the date of approval. It may be renewed for additional two-year terms, provided that the renewal application is filed within the thirty days prior to expiry for marks and up to thirty days in advance of the expiry date for copyrights, in accordance with
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological